奥沙利铂和培美曲塞联合恩度治疗晚期肺腺癌的疗效观察  

Efficacy and safety of combination of oxaliplatin, pemetrexed and endostar in advanced primary adenocarcinoma of lung

作　　者：戴海峰[1] 梁军[2] 廖国清[3] 刘红霞[4] 

机构地区：[1]江苏省肿瘤医院镇痛科,南京210009 [2]北京军区联勤部药品仪器检验所化学室,北京100071 [3]中国人民解放军第309医院肿瘤内科,北京100102 [4]北京中医药大学护理学院,北京100091

出　　处：《中国医学前沿杂志（电子版）》2013年第8期11-13,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的评价奥沙利铂和培美曲塞联合恩度治疗晚期肺腺癌的疗效和不良反应。方法观察50例经病理诊断为Ⅲb和Ⅳ期肺腺癌患者,接受奥沙利铂100 mg/m2,培美曲塞500 mg/m2和恩度15 mg。每3周为1个周期,共6个周期,并使用培美曲塞和恩度对无进展患者进行维持治疗。结果 50例患者,无进展生存期(PFS)为6.1个月,总生存期(OS)为14.7个月。1例完全缓解,22例部分缓解,疾病缓解率为46%,疾病控制率为86%。主要不良反应为乏力(24%)和周围神经损失(18%)、严重的血液系统毒性包括1例Ⅳ级中性粒细胞减少、1例Ⅲ级贫血和1例Ⅲ级血小板减少。结论奥沙利铂和培美曲塞联合恩度治疗晚期肺腺癌疗效确切,耐受性好。Objective The objective of this study was to evaluate the efifcacy and safety of the combination of oxaliplatin, pemetrexed and endostar for advanced primary adenocarcinoma of lung. Methods Fifty patients with stageⅢb~Ⅳpulmonary adenocarcinoma were enrolled. They all received oxaliplatin 100 mg/m2, pemetrexed 500 mg/m2 and endostar 15 mg every 3 weeks for 6 cycles. Maintenance therapy including pemetrexed and endostar was given to patients with non-progressive disease. Results Among the fifty patients, the median PFS and OS were 6.1 (95%CI:5.4 ~ 6.8) and 14.7 (95%CI:13.2 ~ 16.2) months, respectively. One complete and 22 partial remission was observed. The disease remission rate was 46%and control rate was 86%. The most frequent toxicities were fatigue (24%) and peripheral neuropathy (18%). Severe haematological toxicities were grade 4 neutropenia, grade 3 anemia and grade 3 thrombocytopenia (n=1each, 2%). Conclusion The combination of oxaliplatin, pemetrexed and endostar is an effective tolerable regimen for patients with advanced primary adenocarcinoma.

关 键 词：肺腺癌 奥沙利铂 培美曲塞 恩度 联合治疗 

分 类 号：R734.2[医药卫生—肿瘤]